Sally Furniss
New member
National Institutes of Health concluded technology licensing agreement to accelerate development of influenza vaccines
ABC network's Hsu-Hung Chang, Taipei 2010-08-04
Explicitness (3176-TW) and the National Institutes of Health signed a technology licensing agreement, authorized by the National Institutes of cell culture influenza vaccine-related technologies. The authorization contains the National Institutes of Health has completed the certification mdck cell lines, h1n1, h5n1 (bird flu) virus strains, process.
Current National Institutes of Health R & D in the h5n1 influenza vaccine are at National Taiwan University Hospital, the first phase of human clinical trials, and explicitness is granted, it is expected to continue next year, the implementation of Phase II human clinical trial, currently explicitness has been initially the establishment of high-density cell culture system and process technology platform, can be mass produced for human use vaccine antigens, will be a new influenza h1n1 and h5n1 vaccine virus antigen production technology and experience to develop other human vaccine virus antigen in process technology and product development .
http://news.cnyes.com/Content/20100804/KCAZXE6VRH2AI.shtml
ABC network's Hsu-Hung Chang, Taipei 2010-08-04
Explicitness (3176-TW) and the National Institutes of Health signed a technology licensing agreement, authorized by the National Institutes of cell culture influenza vaccine-related technologies. The authorization contains the National Institutes of Health has completed the certification mdck cell lines, h1n1, h5n1 (bird flu) virus strains, process.
Current National Institutes of Health R & D in the h5n1 influenza vaccine are at National Taiwan University Hospital, the first phase of human clinical trials, and explicitness is granted, it is expected to continue next year, the implementation of Phase II human clinical trial, currently explicitness has been initially the establishment of high-density cell culture system and process technology platform, can be mass produced for human use vaccine antigens, will be a new influenza h1n1 and h5n1 vaccine virus antigen production technology and experience to develop other human vaccine virus antigen in process technology and product development .
http://news.cnyes.com/Content/20100804/KCAZXE6VRH2AI.shtml